Comparing two ways to use PCC for traumatic bleeding
Treatments studied
Part of Injuries & trauma clinical trials.
This study compares two approaches to using a blood-clotting medicine (called PCC) for people with severe bleeding after a traumatic injury. It aims to find out whether giving PCC more freely or strictly following guidelines leads to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You were treated for a traumatic injury in the emergency room.
- You arrived at the hospital within 24 hours of your injury.
- Your ABC score (a quick measure of how much blood you might need) is 2 or higher.
- You are not taking blood-thinning medications (like warfarin, rivaroxaban, or heparin).
- You have not had a blood clot, heart attack, or heart stent in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at two medicines (PCC and recombinant activated Factor VIIa) that help blood clot, to see which works better for trauma patients who need a lot of blood transfusions. If you have a severe injury and need many blood transfusions quickly, this study may help identify the best treatment.
This trial tests a clotting factor product called PCC (prothrombin complex concentrate) to treat bleeding episodes in people with hemophilia A who have developed inhibitors. It's for those who are 12–65 and have frequent joint bleeds.
This trial tests giving a blood clotting medicine called fibrinogen to adults with severe bleeding from trauma before they reach the hospital. The goal is to see if it helps control bleeding and improve outcomes.
This trial tests a medicine called 4F-PCC to stop bleeding during complex heart surgery that uses a heart-lung machine. It could help people who have bleeding problems after the surgery.
This trial compares two types of blood tests (a new quick test vs. standard tests) to see which helps doctors better manage bleeding after a severe injury. It is for adults with serious trauma who may have a blood clotting problem.
This study looks at whether aPCC (a clotting medicine) is safe to use for bleeding safety in people with hemophilia A who are already taking emicizumab. It mainly checks side effects and safety after switching to or using aPCC when needed.
Hear when a new Traumatic Bleeding trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.